These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. John M; McKinnon EJ; James IR; Nolan DA; Herrmann SE; Moore CB; White AJ; Mallal SA J Acquir Immune Defic Syndr; 2003 May; 33(1):29-33. PubMed ID: 12792352 [TBL] [Abstract][Full Text] [Related]
4. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. Joly V; Flandre P; Meiffredy V; Leturque N; Harel M; Aboulker JP; Yeni P AIDS; 2002 Dec; 16(18):2447-54. PubMed ID: 12461419 [TBL] [Abstract][Full Text] [Related]
5. Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART). Dai Z; Cai W; Hu F; Lan Y; Li L; Chung C; Caughey B; Zhang K; Tang X Curr Mol Med; 2015; 15(10):975-9. PubMed ID: 26592244 [TBL] [Abstract][Full Text] [Related]
6. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see. Prescrire Int; 2004 Oct; 13(73):180-2. PubMed ID: 15499699 [TBL] [Abstract][Full Text] [Related]
7. [Tenofovir as a strategy to avoid or limit adverse effects]. Portilla J Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():19-24. PubMed ID: 19195434 [TBL] [Abstract][Full Text] [Related]
8. Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor. Domingo P; Sambeat MA; Pérez A; Ordoñez J; Rodriguez J; Vázquez G Antivir Ther; 2003 Jun; 8(3):223-31. PubMed ID: 12924539 [TBL] [Abstract][Full Text] [Related]
9. Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. Cournil A; Coudray M; Kouanfack C; Essomba CN; Tonfack CA; Biwolé-Sida M; Delaporte E; Bork K; Laurent C Antivir Ther; 2010; 15(7):1039-43. PubMed ID: 21041920 [TBL] [Abstract][Full Text] [Related]
10. HIV-associated lipodystrophy syndrome: LioN-HAART cohort: (lipodystrophy in patients on nucleoside-based HAART). Highly active antiretroviral therapy. Lauenroth-Mai E; Schlote F J Acquir Immune Defic Syndr; 2002 Oct; 31(2):253-5. PubMed ID: 12394807 [No Abstract] [Full Text] [Related]
11. [Results of the TRIZAL Study. Therapy change with positive concomitant effect]. MMW Fortschr Med; 2001 Apr; 143 Suppl 1():51-2. PubMed ID: 11373781 [No Abstract] [Full Text] [Related]
12. Lipoatrophy and mitochondrial DNA assays: see all, know all? Brinkman K AIDS; 2005 Jan; 19(1):91-2. PubMed ID: 15627038 [No Abstract] [Full Text] [Related]
13. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa. Palmer M; Chersich M; Moultrie H; Kuhn L; Fairlie L; Meyers T AIDS; 2013 Mar; 27(5):781-5. PubMed ID: 23169331 [TBL] [Abstract][Full Text] [Related]
14. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. McComsey GA; Ward DJ; Hessenthaler SM; Sension MG; Shalit P; Lonergan JT; Fisher RL; Williams VC; Hernandez JE; Clin Infect Dis; 2004 Jan; 38(2):263-70. PubMed ID: 14699460 [TBL] [Abstract][Full Text] [Related]
15. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. Staszewski S; Katlama C; Harrer T; Massip P; Yeni P; Cutrell A; Tortell SM; Harrigan RP; Steel H; Lanier RE; Pearce G AIDS; 1998 Nov; 12(16):F197-202. PubMed ID: 9833847 [TBL] [Abstract][Full Text] [Related]
16. [Opiates withdrawal syndrome after treatment with zidovudine + lamivudine + abcavir in patients with positivity for HIV and treated with methadone]. Pardo López MA; Cuadrado Pastor JM; Pérez Hervás MP; Fernández Villalba E Rev Clin Esp; 2003 Aug; 203(8):407-8. PubMed ID: 12855129 [No Abstract] [Full Text] [Related]
17. Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy. García-Benayas T; Blanco F; de la Cruz JJ; Soriano V; González-Lahoz J AIDS; 2003 Apr; 17(6):921-4. PubMed ID: 12660543 [No Abstract] [Full Text] [Related]
18. Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Aurpibul L; Puthanakit T; Taejaroenkul S; Sirisanthana T; Sirisanthana V Pediatr Infect Dis J; 2012 Apr; 31(4):384-8. PubMed ID: 22124211 [TBL] [Abstract][Full Text] [Related]